COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Dec. 10, 2015 |
Jul. 31, 2019 |
May 30, 2019 |
Mar. 28, 2019 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Mar. 27, 2020 |
|
| Research and development expenses | $ 382,915 | $ 382,915 | |||||
| Description for compensation for services under agreement | two advisory board members shall be issued common stock equivalent to $5,000 the last day of such quarter when meetings are held; (ii) one consultant shall receive common stock equivalent to $6,250 on the last day of each month; (iii) one consultant shall receive a renumeration amount of $10,000-$12,000 per month with an earn out potential of 1% of the Companys majority owned subsidiary, BioCorRx Pharmaceuticals based on certain factors; (iv) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; and (v) one consultant shall receive common stock equivalent to $6,667 on the last day of each month (vi) one consultant shall receive a renumeration amount of $5,500 per month | ||||||
| Common stock issued upon convertible debt | 2,227,575 | ||||||
| Common stock shares issued for services | 10,000 | ||||||
| Office Equipment [Member] | |||||||
| Common stock shares issued for services | 1,658 | ||||||
| Lucido [Member] | |||||||
| Common stock, Shares issued | 200,000 | ||||||
| Alpine Creek [Member] | |||||||
| Payables to Alpine Creek | $ 1,215,000 | $ 85,805 | |||||
| Payable commitment description | In the event that the Company has not paid Alpine Creek $1,215,000 within 24 months of the Effective Date, then the Company shall continue to pay Alpine Creek fifty percent (50%) for each Treatment following the Effective Date until the Company has paid Alpine Creek an aggregate of $1,620,000, with the exception of treatments conducted in certain territories. | On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. | |||||
| Payable per treatment sold | $ 100 | ||||||
| Royalty due | $ 3,503 | ||||||
| Profit holding percentage | 50.00% | ||||||
| BICX Holding Company LLC [Member] | |||||||
| Common stock issued upon convertible debt | 2,227,575 | ||||||
| Convertible Promissory Note | $ 4,160,000 | ||||||
| Conversion agreement description | Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. | ||||||
| Issuance price | $ 2.00 | ||||||
| Gross proceeds | $ 10,000,000 | ||||||
| Charles River Laboratories, Inc. [Member] | Subsequent Event [Member] | |||||||
| Consideration amount | $ 3,024,476 | ||||||
| February 20, 2020 [Member] | Statement of Work Pursuant [Member] | |||||||
| Consideration amount | $ 894,600 | ||||||
| Manufacturing Agreement [Member] | |||||||
| Estimated cost | 578,500 | ||||||
| Consideration amount | 343,648 | ||||||
| Galligan Subscription and Royalty Agreement [Member] | |||||||
| Common stock, Shares issued | 200,000 | ||||||
| Lucido Subscription and Royalty Agreement [Member] | |||||||
| Development and expansion expenses amount | $ 3,000,000 | ||||||
| Subscription and royalty agreement description | Pursuant to the Lucido Subscription and Royalty Agreement: (i) Mr. Lucido purchased shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay Lucido (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”) | ||||||
| Description for the use of proceeds under agreement | The Company will use no less than 65% of the proceeds of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement exclusively to develop, launch and expand the Company’s weight loss program (the “Business”) including sales and marketing activities directly related to the Business, and shall be free to use up to 35% of the aggregate Purchase Price of the Lucido Subscription and Royalty Agreement for general working capital and administration, and for further product development. With the prior written consent of Mr. Lucido, the Company may use more than 35% of the aggregate Purchase Price for general working capital and administration, and for further product development | ||||||